Qualigen Therapeutics, Inc.
QLGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.02 | -0.00 | 0.11 |
| FCF Yield | -22.23% | -19.12% | -29.99% | -11.90% |
| EV / EBITDA | 16.38 | -5.72 | -2.38 | -23.87 |
| Quality | ||||
| ROIC | -3.42% | -85.71% | -310.78% | -50.08% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.05 | 0.65 | 0.60 | 2.65 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -95.01% | 30.91% | 29.97% | -26.09% |
| Safety | ||||
| Net Debt / EBITDA | 22.47 | -2.08 | -0.32 | 1.57 |
| Interest Coverage | -3.14 | -15.88 | -37.01 | -13.27 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |